These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 17051469

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Advantages and disadvantages of current prophylactic vaccines against HPV.
    Madrid-Marina V, Torres-Poveda K, López-Toledo G, García-Carrancá A.
    Arch Med Res; 2009 Aug; 40(6):471-7. PubMed ID: 19853187
    [Abstract] [Full Text] [Related]

  • 23. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 24. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M.
    Cancer; 2007 Jun 25; 111(3):145-53. PubMed ID: 17487850
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
    Society of Gynecologic Oncologists Education Resource Panel Writing groupUniversity of Illinois, Chicago, IL, USA., Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, Wright J.
    Gynecol Oncol; 2006 Sep 25; 102(3):552-62. PubMed ID: 16979432
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer.
    Palmer KE, Jenson AB, Kouokam JC, Lasnik AB, Ghim SJ.
    Exp Mol Pathol; 2009 Jun 25; 86(3):224-33. PubMed ID: 19454268
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines.
    Hampl M.
    Minerva Med; 2007 Apr 25; 98(2):121-30. PubMed ID: 17519854
    [Abstract] [Full Text] [Related]

  • 35. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
    Gauthier A, Martín-Escudero V, Moore L, Ferko N, de Sanjosé S, Pérez-Escolano I, Catalá-López F, Ferrer E, Bosch FX.
    Eur J Public Health; 2008 Dec 25; 18(6):674-80. PubMed ID: 18641420
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prospects and prejudices of human papillomavirus vaccines in India.
    Das BC, Hussain S, Nasare V, Bharadwaj M.
    Vaccine; 2008 May 23; 26(22):2669-79. PubMed ID: 18455843
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Human papillomavirus and cervical cancer: burden of illness and basis for prevention.
    Trottier H, Franco EL.
    Am J Manag Care; 2006 Dec 23; 12(17 Suppl):S462-72. PubMed ID: 17203990
    [Abstract] [Full Text] [Related]

  • 40. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ, O'Shea M, Diaz M, Kim SY.
    Reprod Health Matters; 2008 Nov 23; 16(32):86-96. PubMed ID: 19027626
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.